Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Status:
Not yet recruiting
Trial end date:
2025-08-30
Target enrollment:
Participant gender:
Summary
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of
danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line
treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be
randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to
receive pembrolizumab alone.